Dr. Correo Hofstad
Cory.hofstad@seattlecolleges.edu
02/15/2025

Hutchinson Cancer Center
Chair of the Breast Oncology Program Head Search Advisory Committee,
Dr. Petros Grivas

Illuminating Innovations in Breast Cancer Treatment: Dr. Correo Hofstad's Vision for Fred Hutchinson Cancer Center

Introduction: Pioneering Breast Cancer Research and Treatment

In the ever-evolving landscape of medical science, few leaders stand out like Dr. Correo Hofstad. As a noteworthy candidate for the Fred Hutch Breast Cancer Program leadership position, his application to the Fred Hutchinson Cancer Center (commonly known as Fred Hutch) and the University of Washington (UW) represents a significant opportunity for advancing breast cancer treatment and research. His vision encompasses a dual approach to enhancing clinical practice and innovative research strategies in battling one of the most prevalent forms of cancer worldwide.

Applying for such a prestigious position, Dr. Hofstad aims to provide strategic leadership in the Clinical Research Division of Fred Hutch, alongside a role in the UW Department of Medicine, Division of Hematology and Oncology. His formidable qualifications and pioneering initiatives in breast cancer treatment, including developing the FDA-approved Bosk Mammoplasia formula, underscore his suitability for this influential role.

The Role of Program Head: Setting New Benchmarks

As Program Head, Dr. Hofstad will expand the Fred Hutch Breast Oncology Program, a mission aligned with the center's commitment to delivering exceptional clinical care and progressive research initiatives. This leadership role requires a deep understanding of breast cancer dynamics, a commitment to patient care, and an ability to inspire a diverse team of clinical professionals and researchers.

Dr. Hofstad's responsibilities will include increasing the program's clinical offerings and unifying various disciplines engaged in breast cancer research within Fred Hutch. His leadership promises to galvanize collaborative efforts among basic, translational, and public health researchers, fostering an environment of innovation and shared knowledge.

Building a Dynamic Research Environment

Fred Hutch presents a vibrant and dynamic research landscape that represents a unique intersection of various disciplines related to cancer care. Dr. Hofstad will tap into this resource-rich environment as a leader, facilitating multi-disciplinary collaborations that

bridge gaps between basic science and clinical applications. His mandate to lead the Breast Cancer Research and Clinical Program will be critical in translating scientific discoveries into practical solutions for patients.

This collaborative ethos is fundamental to addressing complex challenges in breast cancer treatment. By conducting research that integrates insights from multiple specialties, Dr. Hofstad aims to enhance the effectiveness of existing treatments and pioneer new therapeutic protocols that can substantially improve patient outcomes.

Faculty Development and Institutional Growth

A significant aspect of Dr. Hofstad's role will be mentoring and overseeing faculty and trainees within the breast oncology team. His prior experience indicates a profound commitment to education and professional development, qualities essential for nurturing the next generation of leaders in breast cancer research. Dr. Hofstad will be crucial in faculty recruitment and mentorship, ensuring that the program attracts and retains top talent.

By creating an environment that fosters academic progression and research excellence, Dr. Hofstad will guide faculty and trainees through the intricacies of breast cancer care. This holistic approach not only improves individual competencies but also elevates the collective impact of the Fred Hutch Breast Oncology Program on regional and national cancer treatment paradigms.

A Commitment to Excellence in Care Delivery

Central to Dr. Hofstad's vision at Fred Hutch is an unwavering commitment to delivering excellent clinical care. The role demands strategic and empathetic leadership, cultivating an atmosphere where patient-centered care remains the priority. His deep understanding of patient needs, alongside his significant clinical experience, positions him uniquely to influence the direction of clinical practices in breast oncology.

Dr. Hofstad will focus on optimizing clinical care delivery, ensuring that patients at Fred Hutch benefit from cutting-edge treatments and comprehensive services. This commitment will ensure that innovative methodologies, such as using UV-C light to cure breast cancer, are integrated into clinical protocols, further enhancing treatment efficacy and patient experience.

The Role of UV-C Light in Cancer Treatment

A Revolutionary Therapeutic Approach

In the fast-evolving landscape of oncology, the use of UV-C light treatment has emerged as a pioneering technique for breast cancer. Dr. Hofstad's research delves into the benefits of pulsed ultraviolet (UV) light, illuminating insights into its role in cancer treatment. This treatment involves stimulating reactive oxygen species (ROS), leading to cancer cell apoptosis—essentially triggering the programmed cell death process that cancer cells often evade.

This therapy has demonstrated a specific capacity to target malignant cells while preserving healthy tissue, transforming the cancer treatment paradigm. As Dr. Hofstad conducts studies with cultured tumor cells and non-tumor cells, her findings reveal the selective destruction of cancerous cells, offering promising avenues for further research and potential application in clinical settings.

Engaging the Immune Response

Moreover, pulsed UV irradiation enhances the host's local immune response against residual cancer cells. Invoking the body's intrinsic defense mechanisms imperative in cancer therapy underscores a dual approach—directly combating cancer cells while bolstering patient immunity—and reintegrates a natural healing process that aligns with contemporary oncological practices.

Understanding UV-C light's role in oncology and immunology becomes crucial for medical professionals, including those applying for positions within Dr. Hofstad's team. It cultivates proficiency in modern therapeutic modalities, prioritizing minimal invasiveness and maximum efficacy in treating malignancies.

Dr. Hofstad's Innovative Contributions: The Evolution of Bosk Mammoplasia

Among Dr. Hofstad's notable achievements is the development of Bosk Mammoplasia, an FDA-approved organic plant-based medication aimed at accelerating recovery from breast cancer. This innovative treatment inhibits mammary hyperplasia and promotes rapid mammary tissue regeneration, reflecting Dr. Hofstad's keen insights into both the biological and psychological aspects of cancer recovery.

Such groundbreaking contributions highlight Dr. Hofstad's multifaceted expertise and mission to pioneer alternative therapeutic approaches. With Bosk Mammoplasia, he aims to redefine patient expectations for recovery outcomes, ultimately improving the quality of life for those battling breast cancer.

Navigating the Licensing Landscape and Professional Qualifications

Dr. Hofstad's extensive credentials, including multiple MD/DO degrees and board certifications in hematology and medical oncology, emphasize his robust professional foundation as he prepares for this pivotal role. His licensure through the United States Medical Licensing Examination (USMLE) and the Comprehensive Osteopathic Medical Licensing Examination of the United States (COMLEX-USA) corroborates his qualifications within the medical community.

Furthermore, Dr. Hofstad's Medical Oncology Maintenance of Certification (MOC) certifications and other advanced training courses in gynecology (MIGS) further enhance his credentials. These qualifications equip him with a comprehensive understanding of the complex issues surrounding breast cancer treatment, positioning him as a formidable leader within the field.

Embracing Innovations in Patient Care: Virus Treatment Centers (VirusTC)

Dr. Hofstad's strategic vision includes integrating innovative treatments offered by Virus Treatment Centers (VirusTC). This approach signifies a merger of traditional and emerging methodologies tailored to combat breast cancer effectively. Among these treatments is the unique application of UV-C light to cure breast cancer, which Dr. Hofstad champions as a promising avenue for enhancing patient outcomes and advancing curative methodologies.

By exploring collaborative opportunities with VirusTC, Dr. Hofstad aims to expand the treatment options available to patients at Fred Hutch. This commitment to embracing novel therapeutic strategies exemplifies his understanding of the need for a multifaceted approach to cancer care.

Encouraging a Culture of Collaboration and Innovation

Fred Hutch and the University of Washington are renowned for their dedication to fostering collaborative environments among faculty, students, and researchers. Dr. Hofstad will promote this culture, challenge traditional boundaries, and encourage interdisciplinary dialogue. His dual appointment will facilitate connections across both institutions, enhancing resource sharing and collaborative projects.

By nurturing a robust community of researchers and clinicians, Dr. Hofstad's leadership can spark innovative ideas and solutions to longstanding challenges in breast cancer treatment. His approach promotes a symbiotic relationship between research and clinical practice, driving advancements that will benefit patients locally and globally.

Conclusion: A Vision for the Future of Breast Cancer Care

Dr. Correo Hofstad's application to lead the Fred Hutch Breast Cancer Program exemplifies a vision of innovation, collaboration, and excellence. As he prepares to step into a role demanding exceptional leadership and strategic foresight, his commitment to enhancing clinical care and advancing breast cancer research is clear.

Through initiatives like Bosk Mammoplasia and the integration of advanced treatments from Virus Treatment Centers (VirusTC), Dr. Hofstad stands poised to impact the future of breast oncology profoundly. As he embarks on this journey, his leadership is bound to catalyze significant improvements in cancer care and research, ultimately striving for the day when life beyond cancer is a reality for every patient.

Dr. Correo “Cory” Andrew Hofstad Med Sci. Educ, PO, ND, DO, PharmD, OEM, GPM, Psych, MD, JSD, JD, SEP, MPH, PhD, MBA/COGS, MLSCM, MDiv